GlassScriptPhysician profile
Yochai Birnbaum
NPI 1114086931
$21,598.29
in general payments reported to CMS, 2019-2025
9 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,192 · 2023: $1,667 · 2024: $206 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,667 · Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,667.00 |
| Food and Beverage | $366.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,758.00 | 2019-2020 | |
| Astrazeneca Ab | $6,597.60 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,667.00 | 2023 | |
| Abbott Laboratories | $1,175.10 | 2019-2024 | Gallant |
| Pfizer INC. | $228.64 | 2019-2025 | |
| Abiomed | $94.13 | 2019 | |
| Btg International INC. | $37.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.86 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yochai Birnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.